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ABSTRACT
The central nervous system (CNS) includes the brain and spinal cord, where both
possess a blood to brain and a blood to cerebrospinal fluid (CSF) barrier. The bloodbrain barrier (BBB) and blood-CSF barrier (BCSFB) regulate the passage of many
molecules to maintain and protect these sensitive organs from harmful xenobiotics (i.e.
drugs, pollutants, etc.) or physiologic changes (i.e. glucose, ion, or water composition).
These barriers also express ABC transporters, including P-glycoprotein (Pgp) and breast
cancer resistance protein (BCRP), which are known to contribute to efflux of endogenous
toxins and therapeutics from the CNS. Pgp and BCRP expression and activity are a
crucial determinant of drug efficacy in the CNS and have been studied using global
transporter knockout mouse models. Since the CNS compartment and location of
transporters is unique at each barrier site, a global knockout model does not address
questions of how each barrier site contributes to ineffectiveness of drugs getting into the
CNS. This unique composition also makes developing therapeutic strategies more
difficult. In order to look at each barrier independently, we have attempted to generate
conditional knockout mouse models of each transporter and in each barrier site. Our
BBB and BCSFB models will provide insight into the biology of drug movement within
the CNS while considering each barrier site’s contribution.
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CHAPTER 1.

INTRODUCTION

The central nervous system (CNS) includes the brain and spinal cord, where both
possess a blood to brain and a blood to cerebrospinal fluid (CSF) barrier. The bloodbrain barrier (BBB) and blood-CSF barrier (BCSFB) regulate the passage of many
molecules to maintain and protect these sensitive organs from harmful xenobiotics (i.e.
drugs, pollutants, etc.) or physiologic changes (i.e. glucose, ion, or water composition).
The Blood-CSF Barrier
The blood-CSF barrier (BCSFB) contains two different types of barrier cells,
choroid plexus (CP) epithelial cells present within the brain interior, and arachnoid
barrier (AB) epithelial cells surrounding the cranial and spinal CSF that flows around the
CNS.
Arachnoid
Among the brain barriers, the AB has been the least characterized. Meningeal
tissue, consisting of three layers, covers the brain surface. The most exterior layer is the
dura mater, followed by an inner layer of arachnoid mater, and then finally the pia mater
that physically covers the brain. The sub-arachnoid space (SAS), where CSF flows
around the brain and spinal cord, lies between the AB and pia layers. Another type of
arachnoid cell extends from the AB layer into and through the SAS creating a web-like
connection between the AB and pia. These web-like cells are called the arachnoid
trabeculae [1]. It should be made clear that arachnoid trabeculae cells do not have barrier
functions and only the single layer of AB cells create a physical barrier between blood
and CSF fluids. Literature often uses the term “leptomeninges”, which includes the AB
and pial layers of the meningeal tissue, but again only the AB has barrier properties. The
AB functions as a physical barrier as evidenced by the exclusion of an intravascular dye
from the CSF, pia, and brain parenchyma by the AB [1, 2]. Similar to the CP and BBB,
AB cells express tight junction proteins, such as claudin-1, zona occludin-1 (ZO-1), and
junction adhesion molecules (JAMs), to create a physical barrier. In addition, the AB
expresses the epithelial markers desmoplakin, vimentin, and cytokeratin which most
likely play a role in stabilization of tight junction formation by acting as intracellular
links between junctions and the cell cytoskeleton [3, 4]. The AB also possesses a
chemical barrier via expression of major ATP-binding cassette (ABC) transporters on the
cell membrane surface (Figure 1-1A). Within the family of ABC transporters, Pgp and
BCRP expression have only been recently elucidated at the AB [5], therefore there is
much more to be discovered about this barrier.
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Figure 1-1.

Localization of Pgp and BCRP in barrier cells within the CNS.
C

A. Arachnoid barrier cells. B
B. Brain endothelial cells. C. Choroid plexus epithelial
e
cells. The asterisk (*) signifiies that Pgp is not expressed in mouse CP, but otther species
may express Pgp. Arrows inndicate direction of efflux by the transporters.
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Choroid plexus
The CP is located inside each of the four brain ventricles, functioning to produce
CSF for the CNS. CSF is a crucial for preventing brain injury, sustaining the buoyancy
of the brain, and maintaining chemical homeostasis of factors circulating within the CSF
[6]. Unlike the BBB, the CP has fenestrated capillaries without any barrier properties,
meaning these capillaries do not exclude any substances from reaching the CP epithelial
cells. A single layer of epithelial cells forms the barrier layer of the CP. These CP cells
express tight junction (TJ) proteins providing a physical barrier between the blood and
CSF. Claudin-3 is the most abundant, but CP cells also express claudin-1, claudin-2,
claudin-11, JAMs and supporting proteins ZO-1, ZO-2, ZO-3 and cingulin [7]. In
addition to these tight junctions, CP epithelium expresses cadherin-10, an adherens
junction protein, and Į, ȕ-catenin scaffolding proteins to support and maintain the
boundary between blood and CSF fluids [7].
Like the BBB, the CP also expresses drug transporters and drug-metabolizing
enzymes creating a transport and enzymatic barrier. Pgp, BCRP, multidrug resistance
protein (MRP) 1, and MRP4 are members of the ABC transporter family and are the most
highly expressed within the CP epithelium [6, 7]. Pgp has been reported to be expressed
on the apical (CSF-facing) surface or sub-apically within the CP epithelium; however, the
exact membrane localization and/or presence of Pgp at the CP have been controversial in
the literature [7-10]. BCRP is present on the apical surface of CP cells (Figure 1-1C),
while MRP1/4 are localized to the basolateral surface of the CP epithelium [8].
Localization of BCRP at the CP suggests it is involved in facilitating substances into the
CSF contrary to its function at the BBB where BCRP prevents substances getting into the
brain from the blood. Since BCRP is known to transport other endogenous compounds, it
is possible that BCRP transports an endogenous substance required into the CSF, or that
this is a mechanism for removing cellular waste products due to the lack of a blood
barrier. For those data that support Pgp expression on the apical CP surface, these
explanations for why BCRP is located there may also apply.
The Blood-Brain Barrier
The blood-brain barrier (BBB), also called the neurovascular unit (NVU), is
composed of brain endothelial cells, pericytes, neurons, astrocytes, and microglia [11].
Within the NVU, each cell type plays a specific role to support and form the BBB. Brain
endothelial cells express several tight junction and adherens junction proteins to create a
physical barrier between the blood compartment and the brain parenchyma [7]. Tight
junctions, such as claudin-3, claudin-5, occludin, and JAMs are key proteins that
eliminate the paracellular passage of substances. Many of these tight junction proteins
are linked to cytoplasmic scaffolding and regulatory proteins such as ZO-1, ZO-2, ZO-3,
and cingulin to ensure maintenance of the BBB [12]. Disruption of claudin-3 or claudin5 has been shown to cause a severely compromised BBB, even causing death in mice that
lack claudin-5 [12, 13]. Adherens junctions are also very important in maintaining an
intact BBB, specifically vascular E-cadherin (VEC or Cdh5), Į, ȕ, and Ȗ-catenin
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scaffolding proteins. These proteins work to hold endothelial cells together, giving the
BBB structure and support as well as making it possible to form the essential tight
junctions for barrier function [12]. Therefore, disruption of adherens junctions can also
result in a compromised or leaky barrier.
In addition to a physical barrier, brain endothelial cells possess a chemical barrier
between the brain and the blood. This chemical barrier is established by the expression
of many transport proteins and enzymes on the BEC membrane surface. These proteins
maintain brain homeostasis by restricting access of xenobiotics, while simultaneously
facilitating transport of compounds required for brain cell nutrition and survival (i.e.
glucose, amino acids, lipids). ABC transporters such as Pgp, BCRP, and various MRPs
are expressed on the apical or blood-side of endothelial cell membranes of the BBB and
are major contributors in efflux of substances back into the blood (Figure 1-1B) [6-8, 1418]. These neuro-protective proteins are efflux pumps and remove endogenously
generated neurotoxic compounds back into the blood. Brain endothelial cells are
considered to be the primary barrier between the brain and the blood and if this is
dysfunctional or leaky, transporters present on other cell types of the BBB (pericytes and
astrocytic end feet) can act as a second line of defense [12].
Pgp and BCRP: Background and Clinical Relevance in the Brain
Pgp and BCRP are two of the most studied efflux transporters in brain barriers.
Pgp was the first ABC transporter to be discovered and BCRP followed over 20 years
later [19-22].
P-glycoprotein (Pgp)
The multidrug resistance (MDR) transporter, also known as Pgp, MDR1, or
ABCB1, is encoded by the ABCB1 gene. Humans have one isoform, ABCB1/MDR1,
while rodents have two isoforms, Mdr1a and Mdr1b [22, 23]. Expression levels of
Mdr1a and Mdr1b have been characterized to be tissue and age dependent, where Mdr1a
is highly expressed in brain endothelial cells while Mdr1b is not [24, 25]. Mdr1a is
expressed at the brain endothelial cell membrane as early as embryonic day 18 (E18) in
mice and continues to increase in its expression until plateauing at post-natal day 28
(P28) [12]. While Pgp is located and functions in the brain barriers, this protein is not
expressed exclusively in the brain. Pgp is highly expressed on the bile canalicular
membrane in the liver, proximal tubules of the kidney, and apical surface of the intestinal
epithelium [26, 27]. Substrates for Pgp are amphipathic and lipid-soluble, ranging in
molecular weight between 300 and 1000 Daltons [22, 23]. Pgp is considered a
promiscuous transporter because it transports a large variety of substrates that can include
anticancer drugs, steroids, fluorescent dyes, and peptides [22]. Some of these compounds
are also substrates for other ABC transporters such as BCRP. For example, topotecan
(topoisomerase I inhibitor) can be a substrate for three ABC transporters, Pgp, BCRP,
and MRP4 [10].
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Breast cancer resistance protein (BCRP)
Unlike Pgp, BCRP is a half transporter encoded by the ABCG2 gene, where each
half produced must homodimerize with another to create a functional protein to transport
its large range of substrates. These compounds are predominantly, but not limited to,
chemotherapeutic agents. BCRP is most well known for transporting the
chemotherapeutic drug mitoxantrone [21, 28] as well as some endogenous physiological
molecules like protoporphrin IX and pheophorbide a, a chlorophyll breakdown product
[29]. Similar to Pgp, BCRP is also expressed in multiple organs, including the bile
canalicular membrane in liver, proximal tubule in kidney, and apical surface of the
intestinal epithelium.
Drug administration into the CNS and transporter protein effects on disease
Both Pgp and BCRP block drug penetration into the CNS, decreasing the efficacy
of drug treatments developed to target the CNS. Therefore, drug treatment of diseases
such as brain cancer, Parkinson’s disease, Alzheimer’s disease, and even fatal brain
metastasis from other cancers (i.e. breast cancer) extremely difficult [30, 31]. Most
chemotherapeutics or drug treatments are given through intravenous (IV) infusion while
other treatment regimens require treatment to be given intrathecally (IT) by intralumbar
injection in the lower spine. While IV injections are the primary means for drug delivery
into the CNS, the BBB and BCSFB hinder the distribution of therapeutics to the intended
target. A growing number of drugs are being given IT to better treat CSF disease [32],
however, the contribution of AB drug transporters to CSF drug distribution has not been
studied.
Instead of directly affecting drug penetration, Pgp and BCRP have been
implicated in modulating aspects of Alzheimer’s and Parkinson’s disease. Alzheimer’s
patients suffer from accumulation of ȕ-amyloid proteins in the brain, but it has been
reported that Pgp and BCRP may efflux these proteins to protect the brain from its toxic
accumulation [7]. Other literature has also shown that brain capillaries from Alzheimer’s
patients have lower expression of Pgp resulting in decreased ȕ-amyloid clearance [3335]. Parkinson’s disease has also been linked to a reduction of Pgp in brain endothelial
cells [36-38].
Animal models used to study drug concentrations in the CNS
Many studies have utilized global transporter knockout (KO) animal models and
analyzed the CSF as a surrogate for the amount of unbound drug available to the brain
[39-42]. However, this approach does not address the question of how much each barrier
contributes to the distribution of a drug within the CNS. The location of each transporter
within the AB, BBB, and CP barriers must be considered as they may have different
efflux directions and in some cases functionally opposing one another. For example,
BCRP at the CP faces the CSF, facilitating drug entry into the CSF, while BCRP at the
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BBB faces the blood, preventing drug penetration into the brain. An alternative method
would be to use mice with conditional KO (cKO) of transporter proteins at each barrier to
estimate the functional contribution of that drug transporter at the AB, BBB, and CP.
This experimental design is especially relevant for drugs given IT, since they do not
come into contact with the BBB until exported into the blood by transporters in the
BCSFB. Understanding the independent roles each barrier has in protecting the brain
from toxicities may give insight towards the more efficient treatment of CNS illness.
New evidence using fluorescent tracer injections into the CSF suggests administration of
compounds through the CSF can potentially expose the brain to a greater amount of
compound (i.e. drugs). This fluorescent tracer was shown to actually bathe or “wash out”
the brain parenchyma and has been implicated as a main route for waste disposal for the
CNS, including possible ȕ-amyloid clearance [43, 44]. Maybe this same principle applies
to drugs injected into the CSF.
Experimental Approach: Generating Transgenic Animals
The goal of this study was to generate mice with conditional deletion of Pgp or
BCRP in each of the barrier cell types; AB, BBB, and CP. Using the Cre-loxP system, we
used tissue specific promoters to drive Cre expression within the AB [45], BBB [46], or
CP [47]. Each model’s Cre expression was then characterized by mating the Cre mouse
to a tdTomato fluorescent reporter mouse [48]. After characterization, each of the three
Cre models were crossed with Pgp and BCRP-floxed mice to generate a cKO where only
cells expressing the Cre enzyme (AB, BBB, or CP) would lose expression of Pgp or
BCRP protein in that cell.
Cre-loxP System
Cre recombinase (Cre) is a 38kDa enzyme that recognizes loxP sites to mediate
site-specific recombination between two loxP markers. Each loxP site is 34 base pairs
(bp) in length and consists of two 13 bp inverted repeats with an 8 bp spacer that provides
orientation for the overall sequence. If two loxP sites are in the same orientation within a
linear DNA sequence, recombination initiated by Cre results in excision of the loxPflanked DNA sequence [49]. Using the Cre-loxP system allows for flexibility in that a
floxed target mouse line can be bred with any type of Cre expressing mouse line. As an
example, breeding a Cre line that expresses the enzyme ubiquitously with a target floxed
mouse can generate a global knockout mouse model. It is also possible to use an
inducible Cre line to study deletion of a target gene at different time points in
development. Using the Cre-loxP approach to generate global knockouts addresses issues
traditional knockouts may have with lethality or infertility when the gene is deleted in the
whole animal. In spite of all its advantages, the Cre-loxP system has some disadvantages
such as the difficulty in finding a promoter to drive Cre expression in a specific tissue or
cell and as with all transgenic models, expression level and site of integration of the Cre
transgene can affect its success [50].
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CHAPTER 2.

MATERIALS AND METHODS
Animals

Mice were used according to protocols approved by the St. Jude Children’s
Research Hospital Committee on the Use and Care of Animals. Cdh5-Cre [46, 51] (JAX
stock #006137), vWF-Cre [47], LPV-Cre [47], and Ptgds-Cre mice were crossed to
ROSA-tdTomato reporter (referred to as tdTomato) (JAX stock #007914) mice to
validate the targeting of Cre expression in specific cell types such as endothelial cells,
choroid plexus epithelial cells, and arachnoid barrier cells. These three cell types
represent all the brain barriers in the central nervous system, and eventually Cre mice will
be crossed to mice carrying a specific floxed gene of interest.
Generation of Ptgds-Cre Mice
The mouse prostaglandin D2 synthase (mPtgds) promoter was PCR amplified
from the BAC Clone RP23-389G18 (Gensat BX1999; purchased from Children’s
Hospital Oakland Research Institute) with restriction sites MluI in the forward primer (5’gaCGCGTtggtccttccaagaggactg-3’) and EcoRI in the reverse primer (5’ccgGAATTCttgctcagagcagagcagg-3’). The 2018 bp amplified product was subsequently
cloned into CL20MCremCherry vector (received from Dr. John Gray at St. Jude Vector
Lab) at the MluI and EcoRI restriction sites. This CL20MCremCherrry (8971 bp) is a
lentiviral vector that expresses Cre from a promoter that we replaced with the mPtgds
promoter. The cloned mPtgds-CremCherry construct (9519 bp; to provide tissue specific
expression of Cre and this construct also express mCherry so the tissue specificity could
also be characterized in the pups) was then sequenced to validate its identity using the
following sequencing primers (Forward 5’-aggcagggatattcaccatt-3’ and Reverse 5’gcaaacggacagaagcattt-3’). Further, this construct was linearized using MfeI and SfiI
restriction enzymes to remove the bacterial sequences. Finally, this 5629 bp transgene
was submitted to our transgenic core facility to microinject the transgene into FVB
mouse oocytes to generate transgenic founders. The founder lines were bred until the
mice were homozygous for the Cre transgene.
Detection of the Zygosity of Ptgds-Cre Transgene Alleles by Multiplex LigationDependent Probe Assay
Multiplex ligation-dependent probe assay (MLPA) was used for determination of
the zygosity of transgene alleles. During MLPA, an oligonucleotide ligation reaction was
performed, followed by PCR using fluorescein-conjugated primer, such that the amount
of PCR product generated for each genomic sequence is directly proportional to the
number of input copies. For this assay, the genomic DNA samples were isolated from
mouse tail using DNeasy Blood and Tissue Kit (QIAGEN #69506) and adjusted to
approximately 10 ng/μL using DNA suspension buffer (TEKnova #T0221). The mice
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bearing Cre transgene alleles were analyzed by using the MLPA Cre probe set to generate
an amplification product of 117 bp. Three control probes were used to amplify control
sequences elsewhere in the mouse genome were used with amplification products ranging
in size from 108 bp, 114 bp and 136 bp [52]. Each probe set was composed of a 5’ and a
3’ half-probe, each containing unique target specific sequence, stuffer sequence, and
universal primer sequences on their 5’ and 3’ ends, respectively (Table 2-1) [52]. All
probes were synthesized at the standard 25nmol (25N) scale of synthesis and purified by
polyacrylamide gel electrophoresis (Invitrogen Life Technologies). Synthesis scales refer
to the amount of starting material present, not the amount of product produced. 3’ halfprobes were synthesized with a 5’ phosphate to facilitate ligation.
MLPA was performed by incubating 50 ng DNA in 5 μL at 98°C for 5 min; after
cooling to room temperature, it was mixed with 1.5 μL of Cre transgene specific probe
mixture (containing 1.5 fmol each probe) and 1.5 μL SALSA hybridization buffer, then
denatured at 95°C for 2 min and hybridized at 60°C for 16 hours. Hybridized probes were
then ligated at 54°C for 15 min by addition of 32 μL ligation mixture. Following heat
inactivation, 40 μL ligation reaction was mixed with 10 μL PCR mixture (SALSA
polymerase, dNTPs, and universal primers, one of which was labeled with fluorescein
(FITC)), and subjected to PCR amplification for 35 cycles. Primer sequences used for
SALSA PCR were 5’-*GGGTTCCCTAAGGGTTGGA-3’ for the forward primer
(*FITC labeled) and 3’-GTGCCAGCAAGATCCAATCTAGA-5’ (unlabeled) for the
reverse primer.
All reagents except probe mixes were from MRC-Holland (Amsterdam, The
Netherlands). Amplification products were diluted in water (1:10) and then 1:9 in HiDi™ formamide (Applied Biosystems, USA) containing 1/36 volume of GeneScan 500
LIZ size standard (Applied Biosystems), to a final dilution of 20 to 200 fold, and then
were separated by size on an 3730XL DNA Analyzer (Applied Biosystems / Life
Technologies). Electropherograms were analyzed by GeneMapper® v5 (Applied
Biosystems), and peak height data were exported to an Excel table. Normalization of
peak height data was done by dividing each Cre transgene peak height by the average
signal from three control probes, followed by division by a similar value calculated from
a set of reference samples known to be heterozygotes for the transgene allele. This ratio
reflects the copy number of the Cre transgene. Control probe sets were used exactly as
previously described [52]. The probe set consists of a 5’ half-probe and a 3’ half-probe.
Each probe contains universal primer sequence, stuffer sequence, and target sequence, the
latter of which is specific for the transgene being assessed. Total length of PCR product
assessed by capillary electrophoresis is shown by the total product length.
Table 2-1.
transgene.
Probe Sequence
Universal
Stuffer
Target

MLPA Cre 5’ and 3’ probe set sequences based on the mouse
5’ Half Probe
GGGTTCCCTAAGGGTTGGA
CGCTACTACTATTAGT
ATGGACATGTTCAGGGATCGCCA
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3’ Half Probe
TCTAGATTGGATCTTGCTGGCGC
AAACTAAATCTAC
GGCGTTTTCTGAGCATACCTGGA

Transgene Localization in Ptgds-Cre Mice Using Fluorescence In Situ Hybridization
(FISH)
The St. Jude Cytogenetic Shared Resource Laboratory isolated lungs from a
Ptgds-Cre mouse carrying two copies of the Cre transgene (determined by MPLA).
Purified Ptgds-Cre plasmid DNA was labeled with a green-dUTP (Alexa Fluor 488,
Molecular Probes) by nick translation. The labeled transgene probe was combined with
sheared mouse DNA and hybridized to metaphase and interphase nuclei derived from the
transgenic mouse lung fibroblast culture in a solution containing 50% formamide, 10%
dextran sulfate, and 2X SSC. The initial FISH assay indicated that the sample had a very
weak homozygous insertion into a probable chromosome 1 location. For the confirmation
assay, the previous process was repeated with the labeled transgene probe and a reddUTP (Alexa Fluor 594, Molecular Probes) labeled chromosome 1 control probe
(Pax3/RP23-260F1/1C4). Both probes were combined with sheared mouse DNA and
hybridized to interphase nuclei and metaphase chromosomes derived from the transgenic
mouse lung fibroblast culture in a solution containing 50% formamide, 10% dextran
sulfate, and 2X SSC. The chromosomes were then stained with 4,6-diamidino-2phenylindole (DAPI) and analyzed. Results indicated that the Ptgds-Cre transgenic mice
have the Ptgds-Cre transgene homozygously inserted into chromosome 1. The transgene
insertion site is at a position that is 47% of the distance from the heterochromaticeuchromatic boundary to the telomere of chromosome 1, an area that corresponds to band
1D-E.
Generation of Pgp-Floxed Mice
The University of Connecticut Health Center Gene Targeting and Transgenic
Facility made the targeting construct and produced mice carrying one floxed allele. The
targeting construct contains loxP sites flanking exon 4 of the ABCB1a gene as well as a
PGKNeo cassette for embryonic stem (ES) cell selection (Figure 2-1A). ES cells were
cultured in selective media containing G418 and gancyclovir to find targeted clones.
Surviving clones were then confirmed by long range PCR to have the correct targeted
allele. These targeted clones were subsequently injected into mouse blastocysts and
implanted into a surrogate mother to generate chimeric mice. Chimeric males were bred
with wild-type female mice to check for germ line transmission of the targeted construct
representing the F2 generation (coat colors blended if transmission successful). The F2
generation of mice were interbred until offspring became homozygous for the Pgp-floxed
alleles. We received sperm of the homozygous Pgp-floxed offspring from transgenic
facility in Connecticut, which was used for in-vitro fertilization in C57BL/6 wild-type
female mouse by the St. Jude Animal Research Center staff. Offspring from this cross
were interbred until again producing homozygous Pgp-floxed mice assessed by PCR.
Deletion of exon 4 of ABCB1a gene, upon introduction of Cre, results in the lack of Pgp
protein due to disruption of its transmembrane domain.
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Figure 2-1. Genomic targgeting scheme for generating Pgp-floxed and BCRPfloxed mice.
CRP-floxed mice.
A. Pgp-floxed mice. B. BC
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Generation BCRP-Floxed Mice
ES cells containing a targeting construct for BCRP were obtained from Dr. Mike
Dean from the National Cancer Institute (NCI). The targeting construct has loxP sites
flanking exon 2 of the ABCG2 gene as well as a Neo cassette for ES cell selection
(Figure 2-1B). Upon arrival, ES cells were cultured in selective media containing G418
and surviving clones were analyzed by Southern hybridization to confirm a correctly
targeted allele. Four correctly targeted clones were sent to the St. Jude Transgenic Core
Facility where these clones were injected into individual mouse blastocysts, then
implanted into a surrogate mother to generate chimera mouse offspring. Chimeric males
were bred with C57BL/6 wild-type female mice to check for germ line transmission of
the targeted construct representing the F2 generation (coat colors blended if transmission
successful). The F2 generation of mice were interbred until offspring became
homozygous for the BCRP-floxed alleles as accessed by PCR and MLPA. Deletion of
exon 2 of ABCG2, in cells expressing Cre, results in the lack of BCRP mRNA or protein
being made.
Whole Organ Fluorescence Analysis
Offspring from all Cre-tomato crosses were collected at two different ages, early
post-natal (P5-7) and adult (6-10wks). Animals were subsequently anesthetized by
isofluorane and perfused through the heart with cold 1x phosphate buffered saline (PBS)
followed by cold 4% paraformaldehyde (PFA, Electron Microscopy Sciences #15710)
diluted in 1xPBS, which was performed by St. Jude Veterinary Pathology Core staff.
Following perfusion, brain, liver, kidneys, and small intestine were removed for whole
tissue fluorescent analysis on a stereoscope (Nikon SMZ1500 stereoscope with Nikon
Intensilight CGFI fluorescence source) where the TRITC filter was used to examine
tdTomato expression. Tissues from all Cre-tomato crosses were processed for frozen or
paraffin slides and further examined by immunofluorescence (IF) or
immunohistochemistry (IHC) respectively after whole organ images were captured.
Immunofluorescence on Frozen Tissue and Image Analysis
Mouse tissues were fixed in 4% PFA overnight at 4°C, then sucrose protected by
incubating them in 15% sucrose in 1xPBS overnight at 4°C, then 30% sucrose in 1x PBS
overnight at 4°C. The next day, tissues were equilibrated in OCT compound (Tissue Tek
#4583, Electron Microscopy Sciences) for 30 minutes, embedded in a mold with OCT,
then frozen in an ethanol bath chilled on a metal block on dry ice. Frozen blocks were
then transferred to the -80°C freezer for storage until sectioning. Blocks were removed
from the freezer and allowed to equilibrate inside the cryostat (Leica) -20°C chamber for
at least 1 hour before sectioning at 15ȝm thickness. Slides were stored at -80°C until
IHC could be performed. Slides thawed on a slide warmer at 37°C for 15-30 minutes
followed by two 10-minute washes with 0.3% Triton X-100 in 1xPBS (PBST). Slides
were blocked with 3% normal donkey serum diluted in PBST (PBST+) for 60 minutes
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followed by an overnight incubation in desired primary antibody (diluted in PBST+) at
4°C (Table 2-2). After primary antibody incubation, slides were washed in PBST three
times for 10 minutes each. Slides were then incubated with appropriate secondary Alexa
Fluor 488, 555 or 647 antibodies (Invitrogen), diluted 1:500 in PBST+, for 2-3 hours.
After secondary incubation, slides were washed in PBST four times for 10 minutes each
followed by mounting with Prolong Gold anti-fade with DAPI (Invitrogen #P36935) and
#1 cover-slips (Thermo Scientific #102450). Images were captured on a Nikon E800
using the 20x dry objective or Marianas confocal microscope using the 40x oil objective.
After capture, images were processed by ImageJ software (64bit, version 1.46r) to
remove non-specific background by adjusting the color range using color balance tools
provided by the ImageJ software.
Immunohistochemistry on Paraffin Embedded Tissue and Image Analysis
Tissues from conditional knockout mouse models were perfused and left to fix in
4% PFA overnight at 4°C, then processed for paraffin slides by the St. Jude Veterinary
Pathology Core. Tissues were sectioned at 4ȝm thickness and slides were stored at room
temperature until IHC could be performed. Slides were deparaffinized and hydrated
through a series of xylene and alcohols according to typical histology practices. Slide
underwent antigen retrieval through incubation in Target Retrieval Buffer, pH 6.0
(DAKO #S1699) for 15 minutes at high pressure within a pressure cooker system. After
retrieval, tissues on slides were peroxidase blocked with 0.3% peroxide and protein
blocked with Sniper Block reagents (Biocare Medical #BS966L). Slides were
subsequently stained with Pgp or BXP-53 primary antibody overnight at 4°C. After
primary antibody incubation, slides were washed in PBST and then incubated with their
respective secondary HRP-polymer (Rabbit on Rodent, Biocare Medical #RMR622H;
Rat on Rodent, Biocare Medical #RT517H) for 30 minutes. Slides were washed in PBST
and incubated with 3,3’-diaminobenzidine chromagen (DAB; Thermo Scientific #TA125-HDX) for 3 minutes. Slides were washed in PBST and then counterstained with
Mayer’s hematoxylin (Thermo Scientific #TA-125-MH) that was diluted 1:5 in distilled
water and filtered prior to applying to slides for 3 minutes. Slides were washed in PBST
and dehydrated through a series of alcohols and xylene. Slides were then mounted with
Permount (Fisher #SP15-500) and coverslipped. Slides were left on a flat surface until
dry, then examined on a Nikon Eclipse Ti microscope with a 10-20x dry objective.
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Table 2-2.
Primary antibody dilutions, host species, and manufacturer
information for immunofluorescence and immunohistochemistry.
Antibody IF Dilution
Pgp
BXP-53
CD31
GFAP
Desmin

1:50,000
1:2,000
1:300
1:500
1:200

IHC Dilution
1:400,000
1:2,000
n/a
n/a
n/a

Host
Species
Rabbit
Rat
Goat
Rabbit
Mouse

Manufacturer
Dr. John Schuetz, SJCRH
Enzo #ALX-801-036
R&D Systems #AF3628
DAKO #Z0334
Novus Biologicals #NBP1-42133

Notes: BXP-53 (BCRP antibody), CD31 (endothelial surface marker), GFAP (glial
filament associated protein), Desmin (pericyte marker). The Pgp antibody was obtained
from Dr. John Schuetz at St. Jude Children’s Research Hospital (SJCRH) in Memphis,
TN. A peptide (SALDTESEKVVQEALDKAREG) coupled to KLH was synthesized
and sent to Rockland Immunochemicals for injection into rabbits to generate the IgG
antibody. The Pgp antibody in the rabbit serum was purified by Invitrogen (previously
Research Genetics) in 2000. The epitope of this antibody recognizes an internal and
highly conserved amino acid sequence on the C-terminal region of Pgp. The classical
MDR1 antibody is the monoclonal C219, but this antibody detects a 200kDa protein
migrating in the same position as myosin, cross-reacts with cerbB2 protein (p185cerbB2),
and recognizes MDR1 and MDR3 isoforms of Pgp.
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CHAPTER 3.

RESULTS

Characterization of Mice Expressing Cre/tdTomato in AB Epithelial Cells
Since there is no Cre transgenic mouse model that targets AB cells, a new AB-Cre
model was generated. The aim was to find a promoter that would drive expression of Cre
in arachnoid cells but not in endothelial cells, CP epithelial cells, or other organs. After
surveying published literature and expression analysis through databases such as the
Allen Brain Institute (ABI) and Gensat, these sources indicated that since both AB and
CP epithelial cells are from a common embryonic origin, it would be possible to generate
AB/CP specific cKO mice representing the BCSFB. The ABI uses in situ hybridization
to look at mRNA expression of genes in the developing and adult mouse brain, while
Gensat uses transgenic mice where promoters of various genes drive green fluorescent
protein (GFP) expression to look at their localization in the mouse developing and adult
brain. L-prostaglandin D synthase (Ptgds) was one of the most highly expressed genes in
AB cells and never indicated to be expressed in brain endothelial cells per evidence
described in published literature and databases described above. Ptgds was chosen to
generate the new AB-Cre model. Ptgds has a dual function in the CNS, one where it is
secreted into the CSF, presumably from AB or CP cells, and another serving as a
transporter protein that binds lipophilic ligands and retinoid molecules [53]. In regards to
its localization, Ptgds has been reported in the leptomeninges (arachnoid and pia
meninges), CP, and oligodendrocytes within the CNS as well as the pigment layer of the
retina, and leydig cells of the testis using in-situ hybridization (ISH) and IHC techniques
[45, 54-57]. An example of Ptgds mRNA expression in mouse brain from ABI can be
seen in Figure 3-1B.
After producing a founder that gave viable offspring and maintained Cre
expression, Ptgds-Cre mice were bred to maintain homozygosity of the Cre transgene and
subsequently crossed with the tdTomato reporter (Figure 3-1A). Seven out of eight
(88%) offspring were positive for tdTomato fluorescence and gender did not influence
fluorescence expression. However, increasing age seemed to correlate with increase in
tdTomato signal meaning older mice had more tdTomato expression than young mice
(Figure 3-1C). Ptgds-Cre/tomato offspring expressed tdTomato in a variety of cell types
including, AB cells, some cell in the NVU (possibly endothelial cells), CP epithelium,
liver hepatocytes, kidney tubules, and intestinal epithelium (Figure 3-1D).
IHC was used to elucidate which cells of the NVU were expressing tdTomato.
The NVU is composed of endothelial cells, pericytes, and astrocytes. Using the vascular
marker CD31 we concluded that tdTomato, driven by the Ptgds promoter, was likely
expressed in endothelial cells of the brain due to the overlapping pattern seen between
CD31 (green) and tdTomato (red) in Figure 3-2A. Co-localization of colors green and
red result in orange color, but sometimes intensity of one color is greater than the other
resulting in a more red or a more green overlap. We ruled out Cre expression in other
cell types that contribute to the NVU, such as pericytes and astrocytes, using their
respective markers desmin and glial fibrillary acidic protein (GFAP). These IHC studies
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Figure 3-1.

TdTomato reporter expression in Ptgds-Cre/tomato mice.

A. Activation of the tdTomato reporter when bred with Ptgds-Cre mice. B. ISH (left
panel) and expression (right panel) analysis of endogenous Ptgds mRNA in adult mouse
brain from the Allen Brain Atlas. The colored scale bar represents level of expression;
blue being the lowest expression and red being the highest expression. Clearly, the
leptomeninges and choroid plexi are highly expressing Ptgds. C. Representative images
of tdTomato expression of whole brain, liver, kidney, and intestine from age matched
Ptgds-Cre/tomato and control (Cre negative) tomato mice (pups n = 6, adults n = 10). D.
Representative images of frozen sections of Ptgds-Cre/tomato (n = 8) and control (Cre
negative) tomato brain, liver, kidney, and intestine at 20X magnification. Dashed lines
indicate the edge of the arachnoid barrier tissue on the surface of the brain.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. C, brain cortex. CB,
cerebellum. AB, arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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Figure 3-1.

Continued.
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Figure 3-2. Immunohistochemistry with NVU markers to validate tdTomato
expression in the brain of Ptgds-Cre/tomato mice.
A. Frozen brain sections stained with CD31 (endothelial cells in green), while Cre is
expressed by tdTomato in red. B. Frozen brain sections stained with pericyte marker
Desmin (green), while Cre is expressed by tdTomato in red. C. Frozen brain sections
stained with antibodies to GFAP (astrocytes in grey) and CD31 (endothelial cells in
green), while Cre is expressed by tdTomato in red.
Notes: Cell nuclei (blue) are stained with DAPI and all images were captured at 40X
magnification. AB, arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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showed little overlap between pericyte and astrocyte markers with tdTomato fluorescence
(Figure 3-2B and C). This result further supported tdTomato expression within brain
endothelial cells of the Ptgds-Cre model. TdTomato expression was seen in brain
endothelial cells of seven out of eight animals characterized. The remaining animal was
the only one negative under stereoscope and tissue section analysis. AB expression of
tdTomato in the Ptgds-Cre/tomato mice was also varied yielding five positive animals out
of eight. The remaining three animals were either negative from stereoscope analysis or
at a young postnatal age (P4) with tdTomato expression only in the brain endothelial
cells. According to the ABI, Ptgds expression begins at embryonic age 13.5 (E13.5) and
should be fully expressed in mice at E18.5, so these young pups should be positive for
tdTomato at P4. Other published literature also supports expression of Ptgds in 8-13
week old rats [55].
Another striking result was the inconsistency of CP expression in our Ptgds-Cre
model. CP expression of tdTomato was seen in only one out of eight (12.5%) animals,
whereas the literature indicated the Ptgds gene would also be highly expressed in CP.
Animals negative for CP expression of tdTomato were of varying ages P4 through 7
weeks old, resulting no correlation with age. The animal with positive tdTomato in CP
was 6 weeks old. This unexpected expression may be due to the Ptgds-Cre transgene
insertion location within the mouse genome. FISH analysis revealed insertion of the
Ptgds-Cre transgene into chromosome 1 within band regions D-E, but this location is not
specific enough to say whether or not the insertion is interfering with any essential genes.
Specifically genes or genetic elements that cause reduced expression of tdTomato in the
CP or cause tdTomato expression to be in the brain endothelial cells.
The tdTomato expression in liver, kidney, and intestine was also analyzed by the
same IHC method, where CD31 and transporter markers were used. This was done to
compare native tdTomato expression in respect to Pgp and BCRP localization in the
brain, liver, kidney, and intestine as well as vasculature sites within these organs. Slides
with sequential frozen sections of brain, liver, kidney, and intestine tissue from PtgdsCre/tomato mice were used. Using sequential sections allows for comparison of similar
areas when looking at expression of different proteins. For example, brain sections
stained for Pgp, CD31, and BCRP were only 15 ȝm apart making it easier to correlate a
location relationship between all three markers. As stated previously, CD31 and
tdTomato seem to co-localize in endothelial cells of the brain, but there seems to be a
lack of co-localization in the vasculature of peripheral tissues, except for in the intestine
and possibly the liver (Figure 3-3B). The tdTomato expression in liver, kidney, and
intestine also seemed to vary animal-to-animal. We confirmed Pgp and BCRP
expression in the AB and BBB, while Pgp and BCRP had differing expression patterns in
the CP. Pgp is not expressed in mouse CP, but BCRP was expressed on the apical (CSFfacing) surface of CP epithelial cells (Figure 3-3A). IHC analysis confirmed the
presence of Pgp and BCRP within the bile canaliculi of liver, kidney tubules, and apical
surface of intestinal epithelium seen in Figure 3-3B. By comparing transporter
localization at each tissue site with tdTomato expression, we concluded that Pgp and
BCRP will be deleted in the AB and BBB of the brain, as well as kidney tubules of
Ptgds-Cre mice when bred with transporter floxed mice.
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Figure 3-3. Immunohistochemistry with CD31, Pgp, and BCRP markers in
comparison to native tdTomato expression in Ptgds-Cre/tomato mice.
A. Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp,
and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification. B. Sequential
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker),
Pgp, and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification.
Notes: Arrows indicate the edge of the AB layer. Cell nuclei (blue) are stained with
DAPI. Red color represents the tdTomato fluorescent reporter, which is an indicator of
Cre expression. Green color indicates antibody staining for CD31, Pgp, or BCRP. AB,
arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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Figure 3-3.

Continued.
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Characterization of Mice Expressing Cre/tdTomato in Endothelial Cells
Two mouse models targeting endothelial cells were analyzed, one using the vWF
promoter and another using the vascular E-cadherin (Cdh5 or VEC) promoter to drive
Cre expression in mouse endothelial cells. The vWF-Cre model was the first to be
characterized, but due to heterogeneous results an alternative model was needed and
Cdh5-Cre was chosen.
vWF-Cre model targeting brain endothelial cells
The previously characterized mouse model vWF-Cre, was generated by Dr.
Rodney Ho and had shown positive Cre expression specifically in brain endothelial cells
[47]. Von Willebrand factor (vWF) is large glycoprotein produced by endothelial cells
that binds and stabilizes Factor VIII (clotting cascade component) in the circulation [58].
After breeding vWF-Cre mice with the tdTomato reporter (Figure 3-4A), the resulting
offspring showed that Cre, as expressed by tdTomato fluorescence, was not uniform in
any tissues or cell types, varied among animals, and was not confined to the brain shown
by whole organ stereoscope and frozen tissue sections (Figure 3-4B and C). Some
brains were completely negative for tdTomato while others expressed the fluorescent
reporter in only one brain hemisphere (Figure 3-4B). Tissue sections also revealed
cellular heterogeneity of Cre expression in brain endothelial cells, choroid plexus
epithelial cells, intestinal epithelium, and hepatocytes (Figure 3-4C).
IHC with the vascular marker CD31 was the final test to see how well the vWFCre model would work for us. The conclusion was that CD31 hardly ever co-localizes
with the tdTomato expression due to the lack of tdTomato expression in endothelial cells
of the vWF-Cre/tomato model (Figure 3-5). Co-localization of CD31 (green) and
tdTomato (red) should result in an orange color, in which analysis of the vWF-Cre/tomato
model showed little to none. Arteries at the brain surface were also negative for
tdTomato expression indicating this was not just a phenomenon of small vessels or
capillaries. No correlation could be concluded about any expression difference between
genders due to its highly sporadic expression pattern. Based on age, generally, adult
mice (6-10wks) positive for tdTomato had a slightly higher expression level than pups
(P5), but ultimately our findings indicate that this model is not be suitable for targeting
endothelial cells in hopes of generating a conditional knockout mouse. It has been
reported that the portion of the promoter used to make the vWF-Cre mouse does not
target all endothelial cells, which supports what we have seen in the brain vasculature
[59, 60].
Cdh5-Cre model targeting endothelial cells
Characterization began again with the Cdh5-Cre mouse model distributed by
Jackson Laboratories. The Cdh5 gene encodes a transmembrane vascular E-cadherin
protein also known as CD144, which has been shown to be required for the maintenance
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Figure 3-4.

TdTomato reporter expression in vWF-Cre/tomato mice.

A. Activation of the tdTomato reporter when bred with vWF-Cre mice. B.
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine
from age matched vWF-Cre/tomato and control (Cre negative) tomato mice (pups n = 8,
adults n = 9). Multiple animals are included to show the heterogeneity of tdTomato
expression for this model. C. Representative images of frozen sections of vWFCre/tomato (n = 7) and control (Cre negative) tomato brain, liver, kidney, and intestine at
20X magnification.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. AB, arachnoid barrier.
BBB, blood-brain barrier. CP, choroid plexus.
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Figure 3-4.

Continued.

27

Figure 3-5. Immunohistochemistry with CD31 in comparison to native tdTomato
expression in vWF-Cre/tomato mice.
Frozen brain, liver, kidney, intestine sections stained with CD31 (endothelial cell marker)
antibody. Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. Green color indicates
antibody staining for CD31 as indicated. Images captured at 20X magnification.
Notes: AB, arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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of selective properties of the endothelial cells of the BBB [46, 51]. Cdh5-Cre mice were
crossed with tdTomato reporter mice (Figure 3-6A) and all resulting offspring were
positive for tdTomato fluorescence, an output of Cre, in endothelial cells. TdTomato
fluorescence was not different between male and female mice, but did seem to increase
(more intense tdTomato fluorescent signal) with increase in age from P7 to adult (6
weeks) by whole organ stereoscope analysis (Figure 3-6B).
Upon examining tissue sections for this difference, all ages seemed equal in
intensity (Figure 3-6C), so the differential may be an artifact of looking at whole organs
versus thin tissue slices. Cdh5-Cre/tomato mice show fluorescent signal in the brain
vasculature including choroid plexus fenestrated capillaries as well as endothelial cells in
liver, kidneys, and intestine shown in Figure 3-6C. Its important to note that this model
does not express tdTomato in the other CNS barrier cells, such as AB or CP epithelium;
as our goal is to target one barrier at a time. IHC with endothelial cell marker CD31 was
performed on frozen tissue sections to again look at the co-localization of CD31 (green)
and tdTomato (red). We expected to see co-localization (yellow/orange color) in
endothelial cells from all organs examined and our results show this (Figure 3-7A and
B).
In addition to CD31 IHC, we also performed this experiment with antibodies to
our ABC transporters of interest, Pgp and BCRP, to show their location in comparison to
the tdTomato expression. Pgp and BCRP are expressed at the luminal surface of brain
endothelial cells and play a major role in drug efflux from the brain parenchyma into the
blood. However, these ABC transports are not found in peripheral endothelial cells, for
example in the vasculature of organs such as liver, kidneys, or intestine. We found in our
Cdh5-Cre/tomato mice that the brain endothelial cells, which make up a portion of the
BBB, express tdTomato, Pgp, and BCRP as seen by the similar vascular staining pattern
in Figure 3-7A. Using this model we can conditionally knockout Pgp or BCRP in the
brain endothelial cells exclusively since Pgp or BCRP are not expressed in any
endothelial cells outside the CNS.
Characterization of Mice Expressing Cre/tdTomato in CP Epithelial Cells
In addition to vWF-Cre, Dr. Rodney Ho generated a LPV-Cre mouse model to
target the choroid plexus epithelial cells to express Cre [47]. This model differs from
others in that it uses a viral control region, specifically a lymphotropic papova virus, to
drive Cre expression in the transgenic animal. It has been reported in the literature that
by using this control region to drive SV40 expression, CP specific tumors arise in mice
[61, 62]. In order to validate this finding and analyze other brain barriers, we crossed the
LPV-Cre mice with the tdTomato reporter (Figure 3-8A). Resulting offspring should
express tdTomato in the CP epithelium only, indicating those cells express the Cre
enzyme. The tdTomato expression could not be visualized by whole organ stereoscope
due the internal location of the CP in the brain, but stereoscope analysis did confirm all
other organs to be negative for tdTomato (Figure 3-8B). Tissue sections were examined
to look for tdTomato expression in the CP, where we found the CP was positive but very
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Figure 3-6.

TdTomato reporter expression in Cdh5-Cre/tomato mice.

A. Activation of the tdTomato reporter when bred with Cdh5-Cre mice. B.
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine
from age matched Cdh5-Cre/tomato and control (Cre negative) tomato mice (pups n = 9,
adults n = 9). C. Representative images of frozen sections of Cdh5-Cre/tomato (n = 7)
and control (Cre negative) tomato brain, liver, kidney, and intestine at 20X magnification.
Dashed lines in the AB column indicate the edge of the arachnoid barrier tissue on the
surface of the brain. Dashed lines in the CP column indicate to boundary of the brain
ventricle that contains the CP.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. AB, arachnoid barrier.
BBB, blood-brain barrier. CP, choroid plexus.

31

32

Figure 3-6.

Continued.

33

Figure 3-7. Immunohistochemistry with CD31, Pgp, and BCRP markers in
comparison to native tdTomato expression in Cdh5-Cre/tomato mice.
A. Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp,
and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification. B. Sequential
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker),
Pgp, and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. Green color indicates
antibody staining for CD31, Pgp, or BCRP. AB, arachnoid barrier. BBB, blood-brain
barrier. CP, choroid plexus.

34

35

Figure 3-7.
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Figure 3-8.

TdTomato reporter expression in LPV-Cre/tomato mice.

A. Activation of the tdTomato reporter when bred with LPV-Cre mice. B.
Representative images of tdTomato expression of whole brain, liver, kidney, and intestine
from age matched LPV-Cre/tomato and control (Cre negative) tomato mice (pups n = 9,
adults n = 15). C. Representative images of frozen sections of LPV-Cre/tomato (n = 4)
and control (Cre negative) tomato brain, liver, kidney, and intestine at 20X magnification.
Dashed lines indicate the boundary of the brain ventricle that contains the CP.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. AB, arachnoid barrier.
BBB, blood-brain barrier. CP, choroid plexus.
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Figure 3-8.

Continued.
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weak. TdTomato expression was not visualized in any endothelial or AB cells, and did
not differ between males and females, but mice did seem to show a correlation of
increasing fluorescent signal with increase in age from P8 to adult (7 weeks) seen in
Figure 3-8C.
For further characterization, we also performed IHC with CD31, Pgp, and BCRP
markers. TdTomato expression did not co-localize with CD31 (no yellow/orange color)
indicating this LPV-Cre model does not have any expression within endothelial cells.
The staining of BCRP and tdTomato fluorescence seems to be overlapping within the CP
epithelium (Figure 3-9A). BCRP is expressed on the apical (CSF-facing) surface of
mouse CP epithelial cells whereas Pgp is not expressed in mouse CP. Expression of Pgp
at the CP is currently a source of contention within the literature [7-10], but our results
conclude that mice do not express Pgp at the CP. Overall, these results suggest this LPVCre model is suitable for conditionally deleting BCRP in the mouse CP, but will make no
impact on Pgp due to lack of expression at this site. The LPV-Cre/tomato mice also do
not show any tdTomato expression in other organs (Figure 3-9B).
Characterization of Pgp and BCRP Conditional Knockout Mice
Ptgds-Cre, Cdh5-Cre, and LPV-Cre mice homozygous for the Cre transgene were
bred with Pgp-flox and BCRP-flox mice homozygous for the floxed allele. Offspring
produced from these crosses were interbred to obtain mice that were confirmed to be
homozygous for both the Cre transgene and the conditional knockout allele, which is
determined by MLPA and PCR genotyping. These homozygous Cre/flox mice are the
conditional knockout (cKO) mice and were used to characterize the status of Pgp and
BCRP proteins in the AB, BBB, and CP of the brain by using traditional colorimetric
IHC. Liver, kidney, and intestine tissues were also analyzed, but the wild-type control
did not stain well and therefore makes it difficult to compare the control and cKO groups.
The same antibody dilution and experimental conditions are not always the same for all
tissues and each tissue may not express the same amount of Pgp or BCRP protein, so
more optimization will be required for these tissues in order to correctly compare control
and cKO groups.
Analysis of immunohistochemistry from Pgp conditional knockout mice
As discussed previously, Pgp can be found at the AB and BBB within the CNS.
Although Pgp’s expression at the CP is controversial, our results consistently prove that
Pgp is not located within the CP of mice. Wild-type mouse brain stained with our Pgp
antibody was used as a positive control, while an isotype control antibody was used for a
negative control. Isotype antibodies are used to control for background issues sometimes
seen when other regions of the antibody or its epitope bind other proteins or structures
non-specifically. Wild-type mouse tissues showed strong Pgp expression in the brain
specifically in the AB and BBB while the CP was negative, as expected.
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Figure 3-9. Immunohistochemistry with CD31, Pgp, and BCRP markers in
comparison to native tdTomato expression in LPV-Cre/tomato mice.
A. Sequential frozen brain sections stained with CD31 (endothelial cell marker), Pgp,
and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification. B. Sequential
frozen liver, kidney, and intestine sections stained with CD31 (endothelial cell marker),
Pgp, and, BXP-53 (BCRP) antibodies. Images captured at 20X magnification.
Notes: Cell nuclei (blue) are stained with DAPI. Red color represents the tdTomato
fluorescent reporter, which is an indicator of Cre expression. Green color indicates
antibody staining for CD31, Pgp, or BCRP. AB, arachnoid barrier. BBB, blood-brain
barrier. CP, choroid plexus.
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Figure 3-9.

Continued.
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For the Pgp-AB KO (Ptgds-Cre x Pgp-flox) mouse, deletion of Pgp at the AB and
possibly at the BBB was expected due to evidence from the Ptgds-Cre/tdTomato
characterization for Cre expression. This ablation pattern of Pgp expression in the brain
was confirmed by IHC (Figure 3-10). It was clear that the AB layer did not express any
Pgp, but the BBB compartment was a little more difficult to interpret. It seems that some
vessels were negative for Pgp staining, while others were positive for Pgp.
Characterization of more animals will help determine if this is a true phenotype or just a
consequence of the genetics of one animal.
In the Pgp-BBB KO (Cdh5-Cre x Pgp-flox) mice, Pgp deletion was expected in
only the endothelial cells due to strong evidence from the Cdh5-Cre/tdTomato
characterization data previously shown above. The AB and CP sites of the cKO brain
looked identical to the wild-type mouse as expected; positive AB and negative CP. The
brain endothelial expression of Pgp in this cKO was present but fainter in comparison to
wild-type (Figure 3-10). This result was very surprising given the strong Cre expression
seen in endothelial cells of the Cdh5-Cre/tomato mouse. There is a possibility that the
floxed allele is not being excised fully for some cells, or Cre is not being expressed in
100% of the endothelial cells of the brain – although the Cdh5-Cre/tdTomato
characterization data suggests Cre/tdTomato is expressed in at least the majority of
endothelial cells of the brain.
The expectation for the Pgp-CP KO (LPV-Cre x Pgp-flox) mouse was that it
would be identical to wild-type due to the lack of Pgp expression in the CP of mice. This
cKO resulted in a Pgp staining pattern identical to a wild-type mouse brain; positive AB
and BBB, while CP was negative (Figure 3-10).
Analysis of immunohistochemistry from BCRP conditional knockout mice
As discussed previously, BCRP can be found at the AB, BBB, and CP within the
CNS. BCRP is also known to be located in bile canaliculi of liver, kidney tubules, and
the surface of intestinal epithelium. Wild-type mouse tissues stained with BXP-53
antibody for BCRP served as a positive control, while an isotope control antibody was
used as a negative control. Wild-type mouse tissues showed strong and consistent BCRP
expression in all three CNS barrier compartments as well as liver, kidney, and intestine as
expected.
For the BCRP-AB KO (Ptgds-Cre x BCRP-flox) mouse, deletion of BCRP at the
AB and possibly at the BBB was expected due to evidence from the Ptgds-Cre/tdTomato
characterization for Cre expression. BXP-53 staining showed no ablation of BCRP at the
AB or BBB. Deletion of BCRP was only seen in the CP, but as an incomplete deletion
(Figure 3-11). This partial ablation could be due to this mouse still having one wild-type
(non-floxed) BCRP allele, as we have not yet reached homozygosity of the BCRP-floxed
alleles yet in our breeding scheme. Recalling the results for the Pgp-AB KO, the
difference in phenotype between the Pgp-AB KO and the BCRP-AB KO is actually quite
telling. As reported above, the Ptgds-Cre mouse has some variation in its offspring
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Figure 3-10. Immunohistochemistry of cKO brain tissue from Cre/Pgp-floxed
mice.
Brain sections from each cKO model stained with our Pgp antibody at 1:400,000 dilution.
Wild-type tissue was from Pgp-floxed mouse (Cre negative). The Pgp-AB KO (n = 1) is
the result of breeding Ptgds-Cre and Pgp-floxed mice. The Pgp-BBB KO (n = 2) is the
result of breeding Cdh5-Cre and Pgp-floxed mice. The Pgp-CP KO (n = 1) is the result
of breeding LPV-Cre and Pgp-floxed mice.
Notes: AB, arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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Figure 3-11. Immunohistochemistry of cKO brain tissue from Cre/BCRP-floxed
mice.
Brain sections from each cKO model stained with our BXP-53 antibody for BCRP at
1:2,000 dilution. Wild-type tissue was from BCRP-floxed mice (Cre negative). The
BCRP-AB KO (n = 1) is the result of breeding Ptgds-Cre and BCRP-floxed mice. The
Pgp-BBB KO (n = 2) is the result of breeding Cdh5-Cre and BCRP-floxed mice. The
Pgp-CP KO (n = 2) is the result of breeding LPV-Cre and BCRP-floxed mice.
Notes: AB, arachnoid barrier. BBB, blood-brain barrier. CP, choroid plexus.
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which resulted in mice not being genetically identical even though all mice stem from the
same transgenic founder. This may be why we are seeing the deletion of transporters in
different compartments between the Pgp and BCRP cKOs generated using the Ptgds-Cre
model. BCRP expression in liver, kidney, and intestine from this cKO was identical to
wild-type indicating no peripheral deletion of BCRP outside of the brain.
BCRP deletion was expected to be in the endothelial cells of BCRP-BBB KO
(Cdh5-Cre x BCRP-flox) mice, due to strong evidence from the Cdh5-Cre/tdTomato
characterization data previously shown above. This cKO showed positive BCRP staining
in the AB and CP, which is identical to wild-type, and partial deletion of BCRP in the
brain endothelial cells (Figure 3-11). This deletion within the endothelial cells is
different from the Pgp-BBB KO in that some vessels are completely negative (indicating
full deletion) and other vessels were identical to wild-type stained vessels. There seemed
to be no correlation to vessel size or location. This result again was very surprising given
the strong Cre expression seen in endothelial cells of the Cdh5-Cre/tdTomato mouse.
There is a possibility that the floxed allele is not being excised fully in some cells or Cre
is not being expressed in all of the endothelial cells of the brain. BCRP expression in
liver, kidney, and intestine from this cKO was identical to wild-type indicating no
deletion of BCRP outside of the brain.
In the BCRP-CP KO (LPV-Cre x BCRP-flox) mice, BCRP deletion was expected
in only the CP, while the AB and BBB should look identical to wild-type. However, IHC
staining with BXP-53 antibody for BCRP showed no CP ablation, resulting in all
compartments staining identical to wild-type mouse brain (Figure 3-11). It is possible
that the viral control region is not driving enough Cre for exon 2 of BCRP to be excised.
No differences were discovered between the CP KO transporter models since the BCRPCP KO is the only CP KO model for mice (due to the lack of Pgp expression in the CP).
BCRP expression in liver, kidney, and intestine from this cKO was identical to wild-type
mice indicating no peripheral deletion of BCRP outside of the brain.
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CHAPTER 4.

CONCLUSION

Ptgds-Cre as a Model of Arachnoid Barrier Deletion of Pgp and BCRP
Although Ptgds-Cre mice have shown to be capable of deleting ABC transporters
from select brain compartments, results have been inconsistent and varied between
animals. The expectation of Ptgds localization in the brain from literature supports
targeting the AB and CP. Originally this model was meant for AB specific deletion of
ABC transporters but upon learning of Ptgds localization in the CP, it could serve as an
ideal BCSFB model. We have shown deletion of Pgp in the AB and partial deletion of
BCRP in the CP (recall this model only had one BCRP-floxed allele), but this has raised
the question of why do we not see the same pattern of ablation when using the same Cre
line. The genotyping was confirmed several times to ensure homozygosity of Cre and the
transporter floxed allele. Currently, these cKO mice, homozygous for Cre and floxed
alleles, are being maintained for continued study. Multiple rounds of breeding could
possibly clear up this variation seen with initial animals, possibly due to an unpure
genetic background of the F1 generation of cKOs. This model can be used for pilot drug
studies looking at pharmacokinetics of specific Pgp and BCRP substrates and their
disposition in the brain.
Cdh5-Cre as a Model of Endothelial Cell Deletion of Pgp and BCRP
The Cdh5-Cre model had the most convincing evidence for Cre localization by
the tdTomato reporter, where it is clear that Cre is localized to endothelial cells only.
Cre/tdTomato expression was consistent and strong without variation between animals.
To our surprise the cKO animals did not recapitulate the tdTomato phenotype in targeting
the endothelial cells. BCRP was lost in only some of the brain endothelial cells while
deletion of Pgp was weak in the BBB cKOs. The promoter seems robust and specific
enough to drive Cre expression in endothelial cells. The only inadequacy could be that
the promoter is not targeting all endothelial cells, but upon evaluating the tdTomato
characterization it seems all or at least a great majority of the endothelial cells are
expressing the Cre enzyme. It is unclear why loss of Pgp and BCRP in the endothelial
cells is not occurring. Characterizing additional animals will aide in confirming the cKO
phenotype for these mice.
LPV-Cre as a Model of Choroid Plexus Deletion of Pgp and BCRP
The LPV-Cre model had the weakest expression of tdTomato (Cre expression).
This raised the question of whether this weak expression would result in enough Cre to
excise the ABC transporter floxed alleles. After staining the cKO tissues for BCRP it
became clear that there is not enough Cre for excision. While the Pgp-CP KO does not
seem useful since mice do not express Pgp in the CP, we initially thought that mice
would express Pgp since other mammals do (i.e. humans). In light of the incapability of
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LPV-Cre to knockout proteins in the CP, the Ptgds-Cre model may serve for this
compartment. We could then simply compare a BBB KO to an AB/CP KO where they
would represent the comparison between the BBB versus the BCSFB, respectively.
Significance of Using Conditional Knockouts of Pgp and BCRP in the Brain
Global Pgp and BCRP knockout mice have shown the importance of these drug
transporters to drug movement, specifically at the BBB. However, due to the unique
localization and expression level of Pgp and BCRP between the AB, BBB, and CP,
global deletion of transporters cannot tease apart each barriers influence on drug
movement. Since many therapeutic agents are or could be substrates from Pgp and
BCRP, it is crucial for the development of novel drugs to estimate the role of each
transporter within each barrier (AB, BBB, and CP). These cKO models have the
potential to answer these questions. As a growing number of drugs are given IT, an
understanding of how drug transporters at the AB and CP modulate or prevent drugs from
blood to CSF will open the door to new strategies to improve drug delivery to the CSF.
IT delivery of drugs is common to patients that experience metastasis of cancer cells to
the CSF. The CSF harbors and protects these cells from chemotherapeutics given IV
with help from drugs transporters at the BBB. With the aide of cKO models, drug
penetration at the BBB versus the BCSFB can be studied as well as the comparison of the
contribution of Pgp and BCRP at each barrier. Blood to CSF drug penetration is no
longer only determined by the BBB and CP, but also influenced by the AB. Adding this
level of complexity also supports the use of cKOs to determine the regional influence of
drug transporters at the three barrier sites.
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